DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival
Therapy resistance and associated liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit. We focused on DNA-dependent protein kinase, DNA-PKcs, encoded by PRKDC and central to DNA damage repair by nonhomologous end joining. Our aim was to explore its roles in hepatocarcinogenesis and as a novel therapeutic candidate. PRKDC was characterized in liver tissues from of 132 patients [normal liver (n = 10), cirrhotic liver (n = 13), dysplastic nodules (n = 18), HCC (n = 91)] using Affymetrix U133 Plus 2.0 and 500 K Human Mapping SNP arrays (cohort 1). In addition, we studied a case series of 45 patients with HCC undergoing diagnostic biopsy (cohort 2). Histological grading, response to treatment, and survival were correlated with DNA-PKcs quantified immunohistochemically. Parallel in vitro studies determined the impact of DNA-PK on DNA repair and response to cytotoxic therapy. Increased PRKDC expression in HCC was associated with amplification of its genetic locus in cohort 1. In cohort 2, elevated DNA-PKcs identified patients with treatment-resistant HCC, progressing at a median of 4.5 months compared with 16.9 months, whereas elevation of activated pDNA-PK independently predicted poorer survival. DNA-PKcs was high in HCC cell lines, where its inhibition with NU7441 potentiated irradiation and doxorubicin-induced cytotoxicity, whereas the combination suppressed HCC growth in vitro and in vivo. These data identify PRKDC/DNA-PKcs as a candidate driver of hepatocarcinogenesis, whose biopsy characterization at diagnosis may impact stratification of current therapies, and whose specific future targeting may overcome resistance..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical cancer research - 21(2015), 4, Seite 925-933 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cornell, Liam [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| doi: |
10.1158/1078-0432.CCR-14-0842 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC196011655X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC196011655X | ||
| 003 | DE-627 | ||
| 005 | 20230714152542.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-14-0842 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC196011655X | ||
| 035 | |a (DE-599)GBVOLC196011655X | ||
| 035 | |a (PRQ)c1841-52c88a4c8742c43790fb7e7c339e29e4c9a10a01e455b03229e111c8363bea9c0 | ||
| 035 | |a (KEY)0273045620150000021000400925dnapkacandidatedriverofhepatocarcinogenesisandtiss | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 36791 |q AVZ |2 rvk | ||
| 100 | 1 | |a Cornell, Liam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Therapy resistance and associated liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit. We focused on DNA-dependent protein kinase, DNA-PKcs, encoded by PRKDC and central to DNA damage repair by nonhomologous end joining. Our aim was to explore its roles in hepatocarcinogenesis and as a novel therapeutic candidate. PRKDC was characterized in liver tissues from of 132 patients [normal liver (n = 10), cirrhotic liver (n = 13), dysplastic nodules (n = 18), HCC (n = 91)] using Affymetrix U133 Plus 2.0 and 500 K Human Mapping SNP arrays (cohort 1). In addition, we studied a case series of 45 patients with HCC undergoing diagnostic biopsy (cohort 2). Histological grading, response to treatment, and survival were correlated with DNA-PKcs quantified immunohistochemically. Parallel in vitro studies determined the impact of DNA-PK on DNA repair and response to cytotoxic therapy. Increased PRKDC expression in HCC was associated with amplification of its genetic locus in cohort 1. In cohort 2, elevated DNA-PKcs identified patients with treatment-resistant HCC, progressing at a median of 4.5 months compared with 16.9 months, whereas elevation of activated pDNA-PK independently predicted poorer survival. DNA-PKcs was high in HCC cell lines, where its inhibition with NU7441 potentiated irradiation and doxorubicin-induced cytotoxicity, whereas the combination suppressed HCC growth in vitro and in vivo. These data identify PRKDC/DNA-PKcs as a candidate driver of hepatocarcinogenesis, whose biopsy characterization at diagnosis may impact stratification of current therapies, and whose specific future targeting may overcome resistance. | ||
| 540 | |a Nutzungsrecht: © 2014 American Association for Cancer Research. | ||
| 650 | 4 | |a Carcinoma, Hepatocellular - genetics | |
| 650 | 4 | |a DNA-Activated Protein Kinase - biosynthesis | |
| 650 | 4 | |a Biomarkers, Tumor - analysis | |
| 650 | 4 | |a Carcinoma, Hepatocellular - enzymology | |
| 650 | 4 | |a Carcinogenesis - metabolism | |
| 650 | 4 | |a Liver Neoplasms - pathology | |
| 650 | 4 | |a Carcinoma, Hepatocellular - pathology | |
| 650 | 4 | |a Carcinogenesis - genetics | |
| 650 | 4 | |a Liver Neoplasms - enzymology | |
| 650 | 4 | |a Nuclear Proteins - biosynthesis | |
| 650 | 4 | |a Liver Neoplasms - genetics | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a DNA Repair | |
| 650 | 4 | |a DNA-PK | |
| 650 | 4 | |a HCC | |
| 650 | 4 | |a cirrhosis | |
| 700 | 1 | |a Munck, Joanne M |4 oth | |
| 700 | 1 | |a Alsinet, Clara |4 oth | |
| 700 | 1 | |a Villanueva, Augusto |4 oth | |
| 700 | 1 | |a Ogle, Laura |4 oth | |
| 700 | 1 | |a Willoughby, Catherine E |4 oth | |
| 700 | 1 | |a Televantou, Despina |4 oth | |
| 700 | 1 | |a Thomas, Huw D |4 oth | |
| 700 | 1 | |a Jackson, Jennifer |4 oth | |
| 700 | 1 | |a Burt, Alastair D |4 oth | |
| 700 | 1 | |a Newell, David |4 oth | |
| 700 | 1 | |a Rose, John |4 oth | |
| 700 | 1 | |a Manas, Derek M |4 oth | |
| 700 | 1 | |a Shapiro, Geoffrey I |4 oth | |
| 700 | 1 | |a Curtin, Nicola J |4 oth | |
| 700 | 1 | |a Reeves, Helen L |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 21(2015), 4, Seite 925-933 |w (DE-627)183917456 |w (DE-600)1225457-5 |w (DE-576)045309310 |x 1078-0432 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2015 |g number:4 |g pages:925-933 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1158/1078-0432.CCR-14-0842 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25480831 |
| 856 | 4 | 2 | |u http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4335075&tool=pmcentrez&rendertype=abstract |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_2181 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 36791 |
| 951 | |a AR | ||
| 952 | |d 21 |j 2015 |e 4 |h 925-933 | ||